Clinical Scorecard: Immune Responses Following COVID-19 Booster Vaccination in Patients Recently Administered Anti-CD20 Antibodies
At a Glance
Category
Detail
Condition
Impaired immune response to COVID-19 vaccination in patients treated with anti-CD20 monoclonal antibodies
Key Mechanisms
Reduced B cell recovery leading to low seroconversion; T-cell responses contribute to viral control
Target Population
Patients with hematologic diseases recently treated with anti-CD20 antibodies within 12 months
Care Setting
Hematology and immunocompromised patient outpatient or hospital settings
Key Highlights
Low seroconversion (~15%) after two mRNA COVID-19 vaccine doses in patients treated with anti-CD20 antibodies.
Third (booster) dose administered at longer intervals (~7 months after second dose) increased humoral response to 42%.
T-cell responses detected in 51% of patients after booster, including many seronegative individuals, indicating cellular immunity despite poor humoral response.
Guideline-Based Recommendations
Diagnosis
Assess anti-S1 IgG antibody levels before and after booster vaccination to evaluate humoral response.
Evaluate T-cell responses against SARS-CoV-2 to assess cellular immunity, especially in seronegative patients.
Management
Administer third (booster) dose of mRNA COVID-19 vaccine at longer intervals (median ~7 months after second dose) in patients recently treated with anti-CD20 antibodies to improve immune response.
Consider timing of vaccination relative to last anti-CD20 antibody administration to optimize B cell recovery and vaccine efficacy.
Monitoring & Follow-up
Monitor both humoral (anti-S1 IgG) and cellular (T-cell) immune responses post-booster vaccination.
Observe for local and systemic adverse events within seven days after vaccination.
Risks
Poor humoral response associated with lower IgM and B cell fractions, prior bendamustine use, and shorter interval between anti-CD20 therapy and vaccination.
Seronegative patients may still have T-cell mediated immunity, which is important for preventing severe disease.
Patient & Prescribing Data
Adults with non-Hodgkin B-cell lymphoma, idiopathic thrombocytopenic purpura, or acquired thrombotic thrombocytopenic purpura treated with anti-CD20 antibodies within 12 months
Third dose of mRNA COVID-19 vaccine administered approximately 7 months after second dose improves humoral and cellular immune responses; BNT162b2 and mRNA-1273 vaccines used; original monovalent vaccines administered.
Clinical Best Practices
Schedule COVID-19 booster vaccination at least several months after last anti-CD20 antibody dose to allow B cell recovery.
Evaluate both antibody and T-cell responses to fully assess vaccine-induced immunity in immunocompromised patients.
Include healthy controls in studies to benchmark immune response levels.
Exclude patients with prior SARS-CoV-2 infection to accurately assess vaccine response.
Collect and analyze adverse event data post-vaccination to ensure safety.
